MedTrace Logo

TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study

NCT04261010 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-09-18

No results posted yet for this study

Summary

This study compare the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after a biologic disease modifying anti-rheumatic drugs (DMARDs)(Adalimumab, Ustekinumab, Guselkumab) in patients with active psoriatic arthritis despite a treatment with a conventional synthetic DMARDs (such as methotrexate).

Conditions

Interventions

PROCEDURE

Global/single cell gene expression profiles obtained from Synovial biopsies

Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.

Sponsors & Collaborators

  • Janssen-Cilag International NV

    collaborator INDUSTRY

  • University Hospital, Ghent

    collaborator OTHER

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Adrien NZEUSSEU TOUKAP, MD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

  • Dirk ELEWAUT, MD, PhD · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2023-09-12
Completion
2023-09-12

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04261010 on ClinicalTrials.gov